Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT01226966
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Prescription is done at the discretion of the prescribing physician as part of normal clinical routine.

Study Details

This observational study is conducted in Europe. The aim of this non-interventional (observational) study is to evaluate the efficacy of liraglutide (Victoza®) and to assess the conditions of use of Victoza® in daily medical practice in France.

Key Dates

Start date
Sep 30, 2010
Status verified
Feb 2017
Primary completion
Nov 30, 2013
Completion
Nov 30, 2013

Study Design

Enrollment
3,152 participants (actual)

Arms

  • Arm: A

Primary Outcome Measure

Percentage of patients still in liraglutide treatment and having a HbA1c (glycosylated haemoglobin) value below 7.0% [ Time Frame: Month 24 ]

Related Studies